Ouro Fino Saúde Animal Participações (OFSA3) Company presentation summary

Company history and milestones

• Founded in 1987, with significant milestones including IPO in 2014 and multiple innovation awards, such as the FINEP Innovation Award in 2005 and 2025.

• Expanded into the pet market in 2000 and biologics in 2007, launching pioneering vaccines and products.

• Notable product launches include LeanVac for swine immunocastration and the world's first single-dose vaccine against Glässer's disease.

• Recognized for innovation and partnership-building, ranking 3rd in the 2024 Open Startups ranking.

• Consistently awarded for workplace excellence and customer service, including Great Place to Work and Reclame Aqui awards.

Market presence and operations

• Operates in major Latin American markets, with direct sales structures in Brazil, Mexico, and Colombia, which together account for over half of the region's meat production.

• Brazil is a global leader in animal protein and pet markets, with the 3rd largest companion animal population and significant projected growth in pet care spending.

• International operations span 16 countries, supported by 19 distributors and a broad SKU portfolio.

Business structure and product portfolio

• Organized into Bovine & Equine, Poultry & Swine, Companion Animals, and International Operations business units.

• Offers a wide range of products, including vaccines, therapeutics, ectoparasiticides, supplements, and hygiene solutions for both production and companion animals.

• Recent launches include Sincromais mineral supplement, Limp & Hidrat Plus for pet ear care, Nexlaner ectoparasiticide, Wellpet chewable for dogs, and Safesui Glasser One vaccine.